Efficacy Data

OS in the PD-L1 CPS ≥ 5 population
More than 3 months survival benefit and a 30 % reduced risk of death with OPDIVO + chemotherapy*

Minimum follow-up: 36.2 months.

PFS in the PD-L1 CPS ≥ 5 population

Median follow-up: 36.2 months.

Duration of Response (DOR) in the PD-L1 CPS ≥ 5 population

Median follow-up: 36.2 months.

Reference:

Janjigian YY, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Jun 10;42(17):2012-2020.

7356-NO-2500069 / Developed 11.11.2025